No. |
DrugBank |
薬物名(臨床試験情報から抽出) |
KEGG DRUG * | KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 | ATL1102 | 1件: Atl1102; | - |
- |
- |
1件: 13 |
2 | Abatacept | 27件: Abatacept; Abatacept (aba); Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept (bms-188667); Abatacept (iv); Abatacept + csdmard; Abatacept + methotrexate; Abatacept + vaccines; Abatacept injection; Abatacept placebo; Abatacept prefilled syringe; Abatacept sc; Abatacept subcutaneous; Abatacept, rituximab or tocilizumab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Bms 188667 (abatacept); Decrease tocilizumab, abatacept; Double-blind abatacept; Intravenous (iv) abatacept; Iv abatacept; Open-label abatacept; Orencia (abatacept); Orencia abatacept; Subcutaneous (sc) abatacept; Subcutaneous abatacept; Subcutaneous(sc) abatacept; Tocilizumab, abatacept; | D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
24件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
3 | Acetaminophen | 8件: Acetaminophen; Acetaminophen tab 650mg; Acetaminophen tablets; Acetaminophen/paracetamol; Oxycodone/acetaminophen; Paracetamol (acetaminophen); Tramadol /acetaminophen; Tramadol hydrochloride + acetaminophen; | D00217 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
13件: 3, 6, 13, 34, 35, 46, 49, 51, 70, 86, 231, 256, 271 |
4 | Acetate | 76件: 11c acetate; 11c-acetate; 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; [n-trans-3-hexenoyl] human growth hormone releasing factor (1-44) acetate; Abiraterone acetate; Acetate; Bazedoxifene acetate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Caspofungin acetate; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortisone acetate; Cosyntropin acetate; Cyclophosphamide/glatiramer acetate; Delmitide acetate; Depot leuprolide acetate 3.75 mg; Desmopressin acetate; Desmopressin acetate trihydrate; Dirucotide acetate; Experimental glatiramer acetate; Flecainide acetate; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Gonadorelin acetate and triptorelin acetate; Human interferon beta-1a and glatiramer acetate; Hydrocortisone sodium acetate; L-lysyl-d-prolyl-l-threonine acetate; Lanreotide acetate; Leuprolide acetate (la); Leuprolide acetate 11.25 mg; Leuprolide acetate 3 month depot; Leuprolide acetate 30 mg; Leuprolide acetate 45 mg; Leuprolide acetate depot; Leuprorelin acetate; Leuprorelin acetate 3.75mg injection; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Luphere depot 3.75mg(leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Macimorelin acetate; Megestrol acetate; Megestrol acetate tablet; Nomegestrol acetate; Phosphate and betamethasone acetate, 2 ml.; Plovamer acetate; Prednisolone acetate; Prednisone acetate; Prednisone acetate tablets; Sodium acetate; Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate; Sotrastaurin (inn) acetate; Tetracosactide acetate; Tocopherol acetate; Tocopheryl acetate; Triptorelin acetate and gonadorelin acetate; Ulipristal acetate; Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; Zuretinol acetate; | - |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
5 | Acetazolamide | 2件: Acetazolamide; Acetazolamide sandoz 250; | D00218 D01196 |
13件: CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9 |
7件: Bile secretion, Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Nitrogen metabolism, Pancreatic secretion, Proximal tubule bicarbonate reclamation |
6件: 13, 90, 115, 155, 225, 230 |
6 | Acetic acid C-11 | - | - |
- |
- |
3件: 13, 86, 88 |
7 | Acetylcysteine | 8件: Acetylcysteine; Acetylcysteine sodium; Glatiramer acetate, n-acetylcysteine; N acetylcysteine; N-acetylcysteine; N-acetylcysteine (nac); N-acetylcysteine capsule; N-acetylcysteine, (nac); | D00221 |
- |
- |
16件: 6, 13, 19, 20, 49, 51, 58, 85, 94, 96, 97, 111, 164, 233, 298, 299 |
8 | Acetylsalicylic acid | 2件: Acetylsalicylic acid; Acetylsalicylic acid at 1st visit,; | D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
10件: 13, 22, 34, 46, 49, 51, 86, 113, 158, 231 |
9 | Activated charcoal | - | D03251 |
- |
- |
8件: 6, 13, 46, 85, 86, 96, 97, 298 |
10 | Acyclovir | 1件: Acyclovir; | D00222 |
- |
- |
5件: 13, 28, 46, 53, 60 |
11 | Adenosine | 4件: 2-cda, 2-chloro-2’-deoxy-beta-d-adenosine; 2-cda, 2-chloro-2’-deoxy-ß-d-adenosine; Adenosine; Autologous ex vivo gene therapy products based on the efs lv encoding for the human adenosine deaminase (ada) gene (efs-ada lv); | D00045 |
4件: ADORA1, ADORA2A, ADORA2B, ADORA3 |
12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
5件: 13, 46, 53, 58, 65 |
12 | Alemtuzumab | 18件: Alemtuzumab; Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994; Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994); Alemtuzumab (campath ); Alemtuzumab (campath); Alemtuzumab (gz402673); Alemtuzumab 0.2 mg; Alemtuzumab 0.3 mg; Alemtuzumab 12 mg; Alemtuzumab 24 mg; Alemtuzumab and rituximab; Alemtuzumab gz402673; Alemtuzumab immunotherapy; Alemtuzumab injection [lemtrada]; Alemtuzumab, rituximab; Filgrastim, alemtuzumab; Transplant conditioning with mobilization and alemtuzumab; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan; | D02802 |
- |
- |
17件: 13, 15, 19, 20, 46, 49, 51, 60, 63, 65, 85, 96, 164, 234, 284, 285, 326 |
13 | Alfuzosin | 1件: Alfuzosin; | D01692 D07124 |
1件: ADRA1A |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 13 |
14 | Amantadine | 10件: 240mg amantadine hcl er tablets; 320mg amantadine hcl er tablets; Ads-5102 (extended release amantadine hcl); Amantadine; Amantadine 300 mg; Amantadine hcl er; Amantadine hcl extended release; Amantadine hydrochloride; Amantadine sulfate; Pk-merz® 200mg/500ml inj(amantadine) , normal saline 500ml inj; | D00777 D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
4件: 6, 8, 13, 127 |
15 | Amiloride | 6件: Amiloride; Amiloride hcl; Amiloride hydrochloride; Amiloride hydrochloride, 2 h2o; Amiloride solution for inhalation; Hydrochlorothiazide/amiloride; | D00649 D07447 |
3件: SCNN1A, SCNN1B, SCNN1G |
2件: Aldosterone-regulated sodium reabsorption, Taste transduction |
3件: 13, 225, 299 |
16 | Anakinra | 8件: Anakinra; Anakinra (kineret®); Anakinra (r-methuil-1ra); Anakinra / kineret; Anakinra and peg stnf-r1; Kineret® (anakinra); Kineret® or anakinra; Response to anakinra associated with methotrexate; | D02934 |
2件: IL1R1, IL1R2 |
15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
17 | Arbaclofen | 7件: Arbaclofen; Arbaclofen er tablets; Arbaclofen extended release tablets; Arbaclofen placarbil; Arbaclofen placarbil 15 mg bid; Arbaclofen placarbil 30 mg bid; Arbaclofen placarbil 45 mg bid; | D09791 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
2件: 13, 206 |
18 | Arbaclofen Placarbil | 4件: Arbaclofen placarbil; Arbaclofen placarbil 15 mg bid; Arbaclofen placarbil 30 mg bid; Arbaclofen placarbil 45 mg bid; | D08861 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
19 | Armodafinil | 1件: Armodafinil; | D03215 |
1件: SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
3件: 6, 13, 84 |
20 | Ascorbic acid | 4件: 2l polyethylene glycol/ascorbic acid; Ascorbic acid; Ascorbic acid (vitamin c); Ascorbic acid vit c; | D00018 |
- |
- |
13件: 10, 13, 49, 62, 86, 96, 97, 192, 206, 211, 212, 254, 284 |
21 | Aspartic acid | - | D00013 |
- |
- |
3件: 13, 75, 299 |
22 | Atacicept | 5件: Atacicept; Atacicept 150 mg; Atacicept 25 mg; Atacicept 75 mg; Atacicept 75 milligram (mg); | D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
4件: 13, 46, 49, 66 |
23 | Atomoxetine | 1件: Atomoxetine; | D02574 D07473 |
1件: SLC6A2 |
1件: Synaptic vesicle cycle |
3件: 6, 8, 13 |
24 | Atorvastatin | 9件: Atorvastatin; Atorvastatin 10mg; Atorvastatin 20mg; Atorvastatin calcium; Atorvastatin tablet 20 mg; Interferon beta treatment to add-on atorvastatin treatment; Interferon beta-1b/atorvastatin group; Lisinopril, losartan, and atorvastatin; Untreated to atorvastatin treatment; | D00258 D00887 D07474 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
17件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
25 | Azathioprine | 33件: 5-asa, prednisone, azathioprine or remicade; Azathioprine; Azathioprine (aza); Azathioprine (aza) or 6-mercaptopurine (6-mp); Azathioprine 25 mg; Azathioprine and allopurinol; Azathioprine in case of endoscopic recurrence; Azathioprine individualised dose; Azathioprine or 6-mercaptopurine; Azathioprine or adalimumab and infliximab; Azathioprine or mesalazine; Azathioprine or methotrexate; Azathioprine or mycophenolate mofetil; Azathioprine weight-based dose; Azathioprine+enteral nutrition; Azathioprine/prednisone; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Continuation of azathioprine; Corticosteroid and azathioprine; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Early immunosuppressants (azathioprine, methotrexate); Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, azathioprine; Overencapsulated azathioprine (imuran) 50 mg tablet; Prednisone - azathioprine; Products containing azathioprine or 6-mercaptopurine; Rituximab (rtx) and azathioprine (aza); Steroids plus azathioprine; | D00238 D03033 |
- |
- |
18件: 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 65, 66, 85, 94, 95, 96, 97, 162 |
26 | Azithromycin | 10件: Azithromycin; Azithromycin (zitromax°); Azithromycin + metronidazole; Azithromycin + n-acetylcystein + inhaled corticosteroid; Azithromycin 250 mg tablets; Azithromycin 250mg capsule; Azithromycin 500 mg film-coated tablet; Azithromycin dihydrate; Po azithromycin; Study medication, azithromycin; | D02134 D06390 D07486 |
- |
- |
6件: 13, 84, 85, 96, 228, 299 |
27 | Baclofen | 5件: Aert, (r)-baclofen; Baclofen; Baclofen 20 mg; Baclofen ir; Rs-baclofen; | D00241 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
5件: 2, 10, 13, 18, 149 |
28 | Baminercept | 3件: Baminercept; Baminercept alfa; Baminercept alfa (bg9924); | D08866 |
1件: LTB |
3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis |
4件: 13, 46, 53, 97 |
29 | Bazedoxifene | 2件: Bazedoxifene; Bazedoxifene acetate; | D03062 |
- |
- |
1件: 13 |
30 | Beta carotene | 2件: Beta carotene; Beta carotene from dunaliella algae; | D03101 |
- |
- |
2件: 13, 96 |
31 | Beta-Alanine | 2件: Beta-alanine; Beta-alanine supplementation; | D07561 |
- |
- |
1件: 13 |
32 | Bevacizumab | 4件: Bevacizumab; Bevacizumab (avastin) and imatinib mesylate (gleevec); Bevacizumab (genitical recombination); Submucosal bevacizumab; | D06409 |
1件: VEGFA |
21件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
33 | Bexarotene | 1件: Bexarotene; | D03106 |
3件: RXRA, RXRB, RXRG |
15件: Adipocytokine signaling pathway, Bile secretion, Gastric cancer, Hepatitis C, Non-alcoholic fatty liver disease (NAFLD), Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer |
2件: 13, 75 |
34 | Biotin | 2件: Biotin; D-biotin; | D00029 |
- |
- |
3件: 2, 13, 20 |
35 | Bisacodyl | 1件: Bisacodyl; | D00245 |
- |
- |
1件: 13 |
36 | Borage oil | 2件: Borage oil; Borage oil 20% gla; | - |
- |
- |
1件: 13 |
37 | Bosentan | 14件: Bosentan; Bosentan (tracleer); Bosentan 125 mg; Bosentan 62.5 mg; Bosentan administration; Bosentan and sildenafil; Bosentan group; Bosentan monohydrat; Bosentan monohydrate; Bosentan mylan; Bosentan, ambrisentan; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Sildenafil 20mg and bosentan 62.5mg; Sildenafil singly or in association with bosentan; | D01227 D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
10件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211 |
38 | Botulinum toxin type A | 3件: Botulinum toxin type a; Botulinum toxin type a (nabota®) injection into the gastrocnemius muscle; Clostridium botulinum toxin type a; | D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
13件: 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226 |
39 | CDP323 | 1件: Cdp323; | - |
- |
- |
1件: 13 |
40 | Calcium | 25件: Amorphous calcium carbonate; Ascal(r) / carbasalate calcium; Atorvastatin calcium; Calcitriol & calcium; Calcium; Calcium and cholecalciferol; Calcium carbonate; Calcium carbonate and alphacalcidol; Calcium channel blockers; Calcium channel blockers (amlodipine, azelnidipine); Calcium citrate; Calcium citrate with vitamin d2; Calcium gluconate; Calcium lactate; Calcium levofolinate; Calcium rosuvastatin; Calcium, dietary; Carbasalate calcium; Crestor tablets (calcium rosuvastatin) film-coated tablets; Crystalline calcium supplements; Ibandronate+alfacalcidol+calcium; Low molecular weight heparin calcium injection; Rosuvastatin calcium; Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin); Vidofludimus calcium; | - |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
41 | Calcium Carbonate | 3件: Amorphous calcium carbonate; Calcium carbonate; Calcium carbonate and alphacalcidol; | D00932 D10802 |
- |
- |
7件: 13, 19, 46, 75, 96, 235, 299 |
42 | Cannabidiol | 6件: Cannabidiol; Cannabidiol (cbd); Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Cannabidiol capsule 5 mg; Cannabidiol oral solution; Cannabidiol tablet 10 mg; | D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
14件: 2, 6, 13, 46, 95, 96, 97, 140, 144, 145, 157, 158, 193, 271 |
43 | Carbidopa | 60件: Accordion pill carbidopa/levodopa; Accordion pill™ carbidopa/levodopa; Accordion pill™ carbidopa/levodopa 50/400 mg; Accordion pill™ carbidopa/levodopa 50/500 mg; Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg); Carbidopa; Carbidopa 20 mg; Carbidopa 27.5 mg; Carbidopa 65 mg capsule; Carbidopa and levodopa 25mg/100mg; Carbidopa fu; Carbidopa levodopa; Carbidopa monohydrate; Carbidopa, levodopa, entacapone; Carbidopa- levodopa; Carbidopa-levodopa; Carbidopa/l-dopa; Carbidopa/l-dopa/entacapone; Carbidopa/levodopa; Carbidopa/levodopa, immediate release; Carbidopa/levodopa/entacapone; Comparator: carbidopa; Continuous intrajejunal infusion of levodopa-carbidopa; Controlled-release levodopa / carbidopa; Entacapone and carbidopa; Immediate release carbidopa/levodopa; Immediate release carbidopa/levodopa 25/100 mg; Levodopa and carbidopa; Levodopa and carbidopa sc solution; Levodopa and carbidopa solution for sc administration; Levodopa carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa carbidopa intestinal gel (lcig); Levodopa, carbidopa, entacapone; Levodopa, carbidopa, odm-104; Levodopa-carbidopa; Levodopa-carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa-carbidopa immediate release (lc-ir) tablets; Levodopa-carbidopa intestinal gel; Levodopa-carbidopa multilayer extended release tablet; Levodopa-carbidopa xl tablet (m); Levodopa-carbidopa-entacapone; Levodopa/carbidopa; Levodopa/carbidopa (4:1); Levodopa/carbidopa (sinemet); Levodopa/carbidopa 100/25; Levodopa/carbidopa hydrate; Levodopa/carbidopa solution; Levodopa/carbidopa(200mg/50mg); Levodopa/carbidopa/entacapone; Nd0612 (levodopa/carbidopa solution); Odm-101 105mg carbidopa; Odm-101 65mg carbidopa; Oral levodopa and carbidopa; Oral levodopa/carbidopa; Sinemet (levodopa/carbidopa); Sinemet plus (levodopa/carbidopa); Sinemet® controlled release (carbidopa/levodopa); Stalevo (levodopa/ carbidopa/ entacapone); Stalevo (levodopa/carbidopa/entacapona); Xp21279 and carbidopa (experimental); | D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
8件: 2, 4, 6, 13, 17, 90, 164, 201 |
44 | Carbonate ion | - | - |
- |
- |
10件: 2, 13, 17, 19, 46, 75, 96, 127, 235, 299 |
45 | Carmustine | 2件: Carmustine; Carmustine, etoposide, cytarabine, and melphalan (beam); | D00254 |
- |
- |
5件: 11, 13, 14, 28, 60 |
46 | Carnosine | 3件: Carnosine; Carnosine supplementation; Carnosine, capsulle, 2 g/day, 8 weeks; | - |
- |
- |
2件: 6, 13 |
47 | Cetirizine | 4件: Antihistamine (cetirizine or equivalent); Cetirizine; Cetirizine hydrochloride; Glatiramer acetate injection with oral cetirizine hydrochloride; | D00664 D07662 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
2件: 13, 35 |
48 | Chloride ion | - | - |
- |
- |
17件: 6, 11, 13, 14, 34, 46, 51, 96, 97, 127, 168, 193, 227, 228, 288, 297, 299 |
49 | Chloroxylenol | - | D03473 |
- |
- |
4件: 6, 13, 46, 168 |
50 | Cholecalciferol | 9件: 5000 iu of cholecalciferol; Calcium and cholecalciferol; Cholecalciferol; Cholecalciferol (vitamin d3); Cholecalciferol 10,000 iu; Cholecalciferol 400 iu; Cholecalciferol and c. xanthorrhiza; Cholecalciferol concentrate; Cholecalciferol, vitamin d3; | D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
15件: 6, 13, 19, 20, 34, 46, 49, 53, 60, 65, 96, 97, 228, 298, 299 |
51 | Cholestyramine | 1件: Cholestyramine; | - |
- |
- |
5件: 13, 79, 93, 254, 297 |
52 | Cisapride | 1件: Cisapride; | D00274 D02092 |
3件: HTR2A, HTR3A, HTR4 |
7件: Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
1件: 13 |
53 | Cladribine | 4件: Cladribine; Cladribine 3.5 mg/kg; Cladribine 5.25 mg/kg; Cladribine tablets; | D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
2件: 13, 94 |
54 | Clemastine | 1件: Clemastine; | D00666 D03535 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 13 |
55 | Clostridium botulinum | 2件: Clostridium botulinum; Clostridium botulinum toxin type a; | - |
- |
- |
1件: 13 |
56 | Coconut | 3件: Coconut; Coconut oil; Coconut oil and epigallocatechin gallate; | - |
- |
- |
1件: 13 |
57 | Coconut oil | 2件: Coconut oil; Coconut oil and epigallocatechin gallate; | D05326 |
- |
- |
1件: 13 |
58 | Coenzyme M | - | - |
- |
- |
9件: 13, 44, 45, 49, 51, 60, 65, 96, 164 |
59 | Corticotropin | 8件: Corticotropin; Corticotropin releasing hormone; Corticotropin-releasing hormone; H.p. acthar gel (repository corticotropin injection); H.p. acthar® gel (repository corticotropin injection); Ovine corticotropin-releasing hormone (ocrh); Repository corticotropin injection; Repository corticotropin injection -treatment extension; | D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
12件: 2, 13, 46, 49, 50, 66, 75, 78, 84, 145, 193, 222 |
60 | Cranberry | 1件: Cranberry; | - |
- |
- |
1件: 13 |
61 | Creatine | 4件: Creatine; Creatine monohydrate; Creatine-13c; Pyruvate, creatine, niacinamide; | - |
- |
- |
12件: 1, 2, 5, 6, 8, 13, 46, 49, 50, 113, 156, 201 |
62 | Curcumin | 5件: Bio-enhanced curcumin soft gelatin capsule; Curcumin; Curcumin (longvida™); Curcumin supplement; Ifn beta 1 a + curcumin (bcm 95); | - |
- |
- |
10件: 13, 46, 49, 67, 74, 94, 96, 97, 139, 299 |
63 | Cyanocobalamin | - | D00166 D03615 D03616 D03617 |
- |
- |
12件: 6, 13, 49, 62, 86, 96, 97, 201, 229, 254, 284, 299 |
64 | Cyclophosphamide | 48件: Busulfan, cyclophosphamide, antithymocyte globulin; Busulfan, cyclophosphamide, atg; Busulfan, cyclophosphamide, atg, gcsf; Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen); Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Campath, fludarabine, cyclophosphamide; Cyclophosphamide; Cyclophosphamide (cy); Cyclophosphamide (cy) (plan 1); Cyclophosphamide (cy) (plan 2); Cyclophosphamide (drug); Cyclophosphamide + pred; Cyclophosphamide 100mg; Cyclophosphamide 150mg; Cyclophosphamide 30; Cyclophosphamide 40; Cyclophosphamide 50mg; Cyclophosphamide 50mg oral tablet; Cyclophosphamide and atg; Cyclophosphamide and steroids; Cyclophosphamide dose level 1; Cyclophosphamide dose level 2; Cyclophosphamide dose level 3; Cyclophosphamide dose level 4; Cyclophosphamide monohydrate; Cyclophosphamide post transplant; Cyclophosphamide(ctx); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Cyclophosphamide, fludarabine; Cyclophosphamide, fludarabine , thymoglobulin; Cyclophosphamide, fludarabine, rabbit atg; Cyclophosphamide, fludarabine, thymoglobulin; Cyclophosphamide,campath ih and tbi; Cyclophosphamide,cyclosporine a; Cyclophosphamide-prednisone-azathioprine; Cyclophosphamide/glatiramer acetate; Fludarabine, cyclophosphamide; Haploidentical hsct using tbi free regimen, ''atg'' with ''post transplant cyclophosphamide''; High-dose cyclophosphamide; Iv cyclophosphamide; Lenalidomide, dexamethasone and cyclophosphamide; Prednisone and cyclophosphamide; Prednisone plus cyclophosphamide; Prednisone, cyclophosphamide; Rituximab and cyclophosphamide iv; Thalidomide, cyclophosphamide and prednisone; | D00287 D07760 |
- |
- |
43件: 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
65 | Cytarabine | 2件: Carmustine, etoposide, cytarabine, and melphalan (beam); Cytarabine; | D00168 D03046 D03637 |
- |
- |
6件: 11, 13, 14, 25, 49, 60 |
66 | D-Aspartic Acid | - | - |
- |
- |
1件: 13 |
67 | D-glucose | 3件: 2-deoxy-2 [f-18] fluoro-2-d-glucose; [18f]fluoro-2-deoxy-2-d-glucose; D-glucose; | D00009 |
- |
- |
6件: 6, 13, 49, 86, 88, 299 |
68 | Daclizumab | 7件: Biib019 (daclizumab); Daclizumab; Daclizumab (anti-cd25 humanized monoclonal antibody); Daclizumab high yield process; Daclizumab hyp; Daclizumab hyp (dac hyp); Daclizumab with greek suufix; | D03639 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
7件: 13, 56, 60, 65, 97, 283, 284 |
69 | Dalfampridine | 5件: Dalfampridine; Dalfampridine er; Dalfampridine-er 10mg; Dalfampridine-er 5mg; Sustained-release oral dalfampridine; | D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
3件: 3, 4, 13 |
70 | Darifenacin | 2件: Darifenacin; Oxybutynin and darifenacin; | D01699 D03654 |
1件: CHRM3 |
9件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
2件: 6, 13 |
71 | Dexamethasone | 35件: Bortezomib/dexamethasone (bd), followed by autologous stc & maintenance bortezomib/dexamethasone; Bupivacaine/epinephrine/dexamethasone; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Control intervention (no dexamethasone); Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Dexamethasone; Dexamethasone (1 cycle); Dexamethasone (4 cycles); Dexamethasone (50mg 1dd6, 3 consecutive days/month); Dexamethasone 0,5mg; Dexamethasone 0.5mg tablet; Dexamethasone 21-phosphate; Dexamethasone 2mg tablets; Dexamethasone abcur; Dexamethasone and rituximab; Dexamethasone parotid irrigation; Dexamethasone sodium phosphate; Dexamethasone sodium phosphate 250 mg/ 10 ml; Dexamethasone sodium phosphate 250 mg/10 ml solution; Dexamethasone sodium phosphate ph. eur.; Dexamethasone soduim phosphate; Dexamethasone, 40 mg; High dose dexamethasone pulses; Intraarticular dexamethasone; Intravenous dexamethasone 1 mg; Lenalidomide and dexamethasone; Lenalidomide+dexamethasone; Lenalidomide, dexamethasone; Lenalidomide, dexamethasone and cyclophosphamide; Melphalan, thalidomide and dexamethasone; Mmf and dexamethasone; Peri-neural dexamethasone 1 mg; Pomalidomide and dexamethasone; | D00292 D00975 D01510 D01615 D01632 D01948 D02174 D02591 D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
20件: 13, 16, 28, 35, 46, 53, 63, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 222, 296, 299 |
72 | Dexchlorpheniramine | 1件: Dexchlorpheniramine; | D07803 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 13 |
73 | Dexrazoxane | 2件: Dexrazoxane; Dexrazoxane (drz) plus mitoxantrone (mx); | D03730 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
1件: 13 |
74 | Dextromethorphan | 9件: Dextromethorphan; Dextromethorphan 30 mg; Dextromethorphan and caffeine; Dextromethorphan hbr and quinidine sulfate; Dextromethorphan hydrobromide; Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg; Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg; Dextromethorphan/quinidine 20mg/10mg (dm/q 20mg/10mg); Dimebon + dextromethorphan; | D00848 D03742 D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
9件: 2, 6, 8, 13, 46, 78, 96, 97, 156 |
75 | Diclofenac | 9件: Comparator: diclofenac; Comparator: diclofenac sodium; Diclofenac; Diclofenac + omeprazole; Diclofenac 50 milligrams; Diclofenac natrium pch retard tablet mga 75mg; Diclofenac sodium; Diclofenac sodium topical gel; Diclofenac sr; | D00903 D00904 D07816 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
4件: 13, 34, 46, 271 |
76 | Dimethicone | - | D01540 |
- |
- |
2件: 13, 96 |
77 | Dimethyl fumarate | 4件: Dimethyl fumarate; Dimethyl fumarate (dmf); Dimethyl fumarate [dmf]; Tecifdera (dimethyl fumarate); | D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
5件: 13, 46, 49, 51, 86 |
78 | Diroximel fumarate | 2件: Diroximel fumarate; Diroximel fumarate (drf); | D11154 |
- |
- |
1件: 13 |
79 | Dirucotide | 2件: Dirucotide; Dirucotide acetate; | D09396 |
- |
- |
1件: 13 |
80 | Docusate | - | D00305 |
- |
- |
7件: 13, 62, 86, 96, 97, 254, 284 |
81 | Domperidone | 3件: Domperidone; Domperidone (drug); Levodopa and domperidone; | D01745 D07868 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
5件: 6, 13, 17, 51, 230 |
82 | Donepezil | 4件: Donepezil; Donepezil hci (drug); Donepezil hydrochloride; Donepezil sandoz; | D00670 D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
9件: 5, 6, 13, 46, 78, 124, 127, 156, 206 |
83 | Doxycycline | 7件: Antimicrobial therapy: co-trimoxazole or doxycycline; Doxycycline; Doxycycline 100 mg capsules; Doxycycline hyclate; Doxycycline hyclate ph.eur; Interferon beta 1a, oral doxycycline; Treatment with systemic therapy (doxycycline); | D00307 D02129 D03903 D03904 D07876 |
- |
- |
15件: 13, 23, 28, 46, 84, 85, 89, 96, 97, 158, 162, 167, 227, 280, 299 |
84 | Dronabinol | 4件: Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Dronabinol; Dronabinol capsule 2,5 mg; Dronabinol capsule 2.5. mg; | D00306 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
5件: 2, 13, 46, 271, 298 |
85 | Duloxetine | 3件: Duloxetine; Duloxetine hydrochloride; Duloxetine hydrochloride (hci); | D01179 D07880 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 6, 13, 49 |
86 | Dydrogesterone | 1件: Dydrogesterone; | D01217 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
1件: 13 |
87 | Eculizumab | 4件: Abp 959 - biosimilar to eculizumab; Eculizumab; Sb12 (proposed eculizumab biosimilar); Soliris (eculizumab); | D03940 |
1件: C5 |
7件: Complement and coagulation cascades, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Pertussis, Prion diseases, Staphylococcus aureus infection, Systemic lupus erythematosus |
7件: 11, 13, 14, 62, 109, 222, 223 |
88 | Efalizumab | 1件: Efalizumab; | D03959 |
1件: ITGAL |
11件: Cell adhesion molecules (CAMs), Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis |
9件: 11, 13, 37, 46, 49, 53, 61, 95, 96 |
89 | Elezanumab | 1件: Elezanumab; | D11355 |
1件: RGMA |
2件: Axon guidance, TGF-beta signaling pathway |
1件: 13 |
90 | Epigallocatechin | 5件: Coconut oil and epigallocatechin gallate; Epigallocatechin; Epigallocatechin gallate; Epigallocatechin-3-gallate (egcg); Epigallocatechin-gallate; | - |
- |
- |
4件: 13, 28, 85, 113 |
91 | Epigallocatechin gallate | 2件: Coconut oil and epigallocatechin gallate; Epigallocatechin gallate; | - |
- |
- |
8件: 6, 13, 17, 28, 85, 113, 206, 299 |
92 | Epinephrine | 4件: Bupivacaine/epinephrine/dexamethasone; Epinephrine; Lap tap bupivacaine/epinephrine; Us tap bupivacaine/epinephrine; | D00095 D00996 D02149 |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
9件: 6, 13, 46, 86, 96, 168, 226, 231, 256 |
93 | Erythropoietin | 4件: Erythropoietin; Erythropoietin human recombinant (eporh); Recombinant human erythropoietin; Recombinant human erythropoietin(rhepo); | D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
9件: 2, 6, 13, 22, 46, 47, 70, 95, 96 |
94 | Escitalopram | 3件: Escitalopram; Escitalopram oxalate antidepressant; Oral escitalopram; | D02567 D07704 D07913 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 2, 6, 13 |
95 | Estradiol | 8件: 5% lidocaine/5 mg/ml estradiol compound cream; Estradiol; Estradiol 2 mg; Estradiol hemihydrate; Ethinyl estradiol; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Ortho-cyclen, ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg; | D00105 D01413 D01617 D01953 D04061 D04063 D04064 D04065 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
5件: 13, 46, 49, 226, 299 |
96 | Estriol | 2件: Estriol; Vaginal estriol; | D00185 D01986 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
2件: 13, 227 |
97 | Eszopiclone | 1件: Eszopiclone; | D02624 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
3件: 6, 13, 46 |
98 | Ethanol | 7件: Andrographis paniculata (ethanol extract); Ethanol; Ethanol (96 per cent); Ethanol 96% gel; Ethanol 98% solution; Ethanol bp; Ethanol gel; | D00068 D02798 D04855 D06542 |
- |
- |
49件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 58, 61, 63, 64, 65, 66, 81, 84, 85, 86, 88, 95, 96, 97, 113, 145, 162, 164, 222, 224, 228, 251, 279, 280, 283, 284, 285, 288, 298, 299, 300, 331 |
99 | Ethinylestradiol | 1件: Ethinylestradiol; | D00554 |
1件: ESR1 |
8件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
4件: 13, 46, 49, 299 |
100 | Etifoxine | 1件: Etifoxine; | D07320 |
- |
- |
1件: 13 |
101 | Etoposide | 2件: Carmustine, etoposide, cytarabine, and melphalan (beam); Etoposide; | D00125 D04107 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
11件: 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 |
102 | Evobrutinib | 2件: Evobrutinib; M2951 (other name: evobrutinib); | - |
- |
- |
3件: 13, 46, 49 |
103 | Febuxostat | 1件: Febuxostat; | D01206 |
1件: XDH |
5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
3件: 2, 6, 13 |
104 | Ferric oxide | - | D04168 |
- |
- |
1件: 13 |
105 | Ferumoxytol | 1件: Ferumoxytol; | D04177 |
- |
- |
1件: 13 |
106 | Filgrastim | 6件: Ep2006 (filgrastim); Filgrastim; Filgrastim (g-csf); Filgrastim hexal; Filgrastim, alemtuzumab; Granulocyte colony-stimulating factor (filgrastim); | D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
28件: 2, 6, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 85, 96, 113, 164, 283, 284, 285, 331 |
107 | Fingolimod | 6件: 0,5 mg fingolimod; Fingolimod; Fingolimod (fty720); Fingolimod 0.5 mg; Fingolimod 1.25 mg; Fingolimod hydrochloride; | D10001 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
4件: 2, 13, 14, 156 |
108 | Firategrast | 7件: Firategrast; Firategrast (usan approved name); Firategrast 150 mg; Firategrast 300 mg; Firategrast gastro-retentive solution; Firategrast immediate release tablet; Firategrast modified release tablet; | D06590 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
109 | Fish oil | 10件: Combination fish oil and borage seed oil; Combination of fish oil and colesevelam; Fish oil; Fish oil concentrate; Fish oil supplement; Fish oil, gamma-linolenic acid; Fish oil, rich in omega-3-acids; Fish oil,rich in omega 3 acids; Lipoic acid (la) with fish oil and la without fish oil; Omega-3 fatty acid fish oil supplement; | - |
- |
- |
7件: 13, 46, 49, 66, 96, 260, 299 |
110 | Fludarabine | 23件: Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen); Busulfan, fludarabine and atg; Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Busulfan, fludarabine, atg, tli; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Campath, fludarabine, cyclophosphamide; Cyclophosphamide, fludarabine; Cyclophosphamide, fludarabine , thymoglobulin; Cyclophosphamide, fludarabine, rabbit atg; Cyclophosphamide, fludarabine, thymoglobulin; Fludarabine; Fludarabine (flu); Fludarabine monophosphate; Fludarabine phosphate; Fludarabine phosphate 30 mg; Fludarabine phosphate 40 mg; Fludarabine, busulfan, thymoglobulin; Fludarabine, cyclophosphamide; Fludarabine, melphalan, thiotepa; Fludarabine/ melphalan; Fludarabine/busulfan; Sq fludarabine; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan; | D01907 D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
17件: 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 326 |
111 | Fludeoxyglucose F-18 | 1件: Fludeoxyglucose f 18; | - |
- |
- |
8件: 6, 13, 34, 46, 53, 84, 127, 300 |
112 | Flumazenil | 4件: 11c-flumazenil; [11c]flumazenil; Flumazenil; Pet with 11c-flumazenil; | D00697 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
5件: 6, 13, 17, 18, 206 |
113 | Fluoxetine | 4件: Amitriptyline, fluoxetine and tramadol alone (control group); Fluoxetine; Fluoxetine hydrochloride; Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group); | D00326 D00823 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
6件: 13, 17, 78, 86, 179, 206 |
114 | Flupirtine | 1件: Flupirtine; | D07978 |
- |
- |
1件: 13 |
115 | Flurbiprofen | 3件: Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Flurbiprofen; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; | D00330 D01475 D02290 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
2件: 13, 46 |
116 | Folic acid | 5件: Folic acid; Folic acid or folate; Folic acid, vitamin b6, vitamin b12; Methotrexate and folic acid; Rituximab, mtx, folic acid; | D00070 |
- |
- |
11件: 6, 13, 46, 49, 62, 84, 86, 96, 97, 254, 284 |
117 | Fumaric Acid | 2件: Fumaric acid; Second-generation fumaric acid; | D02308 |
- |
- |
1件: 13 |
118 | GSK-2018682 | 2件: Gsk2018682; Gsk2018682 cd2 capsule; | - |
- |
- |
1件: 13 |
119 | GSK-239512 | 1件: Gsk239512; | - |
- |
- |
1件: 13 |
120 | Gabapentin | 3件: Gabapentin; Gabapentin prescriptions; Transdermal fentanyl matrix, gabapentin; | D00332 |
5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
7件: 6, 13, 19, 70, 97, 226, 298 |
121 | Gadobenic acid | - | D04283 D08018 |
- |
- |
3件: 13, 86, 88 |
122 | Gadobutrol | 1件: Gadobutrol; | D07420 |
- |
- |
3件: 13, 22, 46 |
123 | Gadolinium | 6件: Gadolinium; Gadolinium contrast; Gadolinium for abdomen; Gadolinium for lower back; Gadolinium-based contrast; Standard gadolinium contrast; | - |
- |
- |
6件: 13, 34, 46, 58, 65, 305 |
124 | Gadoteric acid | 1件: Gadoteric acid; | D08007 |
- |
- |
2件: 13, 53 |
125 | Gadoteridol | 2件: Gadoteridol; Prohance (gadoteridol); | D01137 |
- |
- |
1件: 13 |
126 | Ginkgo biloba | 2件: Ginkgo biloba; Ginkgo biloba pills sig: 300mg/tid; | - |
- |
- |
3件: 6, 13, 90 |
127 | Ginseng | 4件: American ginseng; American ginseng extract ht-1001; Ginseng; Korean red ginseng; | D06772 |
- |
- |
3件: 13, 46, 53 |
128 | Glatiramer | 23件: 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; Cyclophosphamide/glatiramer acetate; Experimental glatiramer acetate; Glatiramer; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Human interferon beta-1a and glatiramer acetate; | D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
4件: 2, 13, 96, 156 |
129 | Glutamic Acid | - | D00007 D04341 |
- |
- |
1件: 13 |
130 | Glycerin | - | D00028 |
- |
- |
6件: 6, 13, 53, 265, 316, 317 |
131 | Gold | 3件: Gold; Gold nanocrystals; Sodium aurothiomalate (intramuscular gold); | - |
- |
- |
5件: 2, 6, 13, 46, 171 |
132 | Green olive | - | - |
- |
- |
3件: 13, 49, 53 |
133 | Guanabenz | 2件: Guanabenz; Guanabenz acetato; | D04375 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
2件: 2, 13 |
134 | Histidine | 3件: Copper histidine; Histidine; L-histidine; | D00032 |
- |
- |
3件: 13, 169, 170 |
135 | Human interferon beta | 6件: Human interferon beta; Human interferon beta 1a (rebif); Human interferon beta-1a and glatiramer acetate; New formulation of rebif - human interferon beta-1a; Recombinant human interferon beta; Recombinant human interferon beta-1a; | - |
- |
- |
6件: 13, 14, 20, 26, 96, 97 |
136 | Human interleukin-2 | 2件: Human interleukin-2; Recombinant human interleukin-2 (rhil-2); | - |
- |
- |
14件: 2, 13, 35, 46, 49, 51, 55, 56, 63, 65, 95, 96, 97, 271 |
137 | Hydrochlorothiazide | 2件: Hydrochlorothiazide; Hydrochlorothiazide/amiloride; | D00340 |
- |
- |
3件: 13, 67, 225 |
138 | Hydroxychloroquine | 16件: Hydroxychloroquine; Hydroxychloroquine (z0188); Hydroxychloroquine + prednisone; Hydroxychloroquine high; Hydroxychloroquine higher dose; Hydroxychloroquine lower dose; Hydroxychloroquine or chloroquine; Hydroxychloroquine reduced; Hydroxychloroquine sulfate; Hydroxychloroquine sulphate; Leflunomide-sulfasalazine-hydroxychloroquine; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate-sulfasalazine-hydroxychloroquine; Sirolimus and hydroxychloroquine; Sulphasalazine + hydroxychloroquine or prednisolone; Versus hydroxychloroquine; | D08050 |
- |
- |
18件: 13, 41, 46, 48, 49, 53, 56, 66, 84, 89, 90, 96, 222, 234, 254, 271, 298, 299 |
139 | Hydroxytyrosol | 2件: Essential - hydroxytyrosol; Hydroxytyrosol; | - |
- |
- |
1件: 13 |
140 | Hydroxyurea | 1件: Hydroxyurea; | D00341 |
1件: RRM2 |
6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway |
8件: 3, 13, 19, 20, 65, 85, 86, 284 |
141 | Ibudilast | 1件: Ibudilast; | D01385 |
8件: CYSLTR1, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PTGIR |
16件: Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Platelet activation, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 2, 13 |
142 | Ibuprofen | 5件: Ibuprofen; Ibuprofen 200mg; Ibuprofen pch tablet 600mg; Rebif new formulation + ibuprofen prn; Rebif new formulation + prophylactic ibuprofen; | D00126 D01122 D04490 D06606 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
6件: 13, 46, 65, 113, 271, 299 |
143 | Idebenone | 2件: Idebenone; Idebenone 150 mg film-coated tablets; | D01750 |
- |
- |
4件: 6, 13, 113, 302 |
144 | Imatinib | 6件: Bevacizumab (avastin) and imatinib mesylate (gleevec); Imatinib; Imatinib mesilate; Imatinib mesylate; Imatinib mesylate (gleevec); Imatinib mesylate 400mg capsule; | D01441 D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
145 | Immune Globulin Human | - | - |
- |
- |
20件: 2, 11, 13, 14, 17, 18, 35, 38, 39, 43, 45, 49, 50, 51, 63, 65, 85, 164, 296, 309 |
146 | Indian frankincense | - | - |
- |
- |
1件: 13 |
147 | Inosine | 2件: 1) inosine 5'-monophosphate; Inosine; | D00054 |
- |
- |
4件: 2, 6, 13, 17 |
148 | Interferon beta-1a | 28件: Avonex (interferon beta 1a); Avonex (interferon beta-1a), biogen idec ltd; Bcd-033 (interferon beta 1a); Bg9418 (interferon beta-1a); Human interferon beta 1a (rebif); Human interferon beta-1a and glatiramer acetate; Interferon beta 1a; Interferon beta 1a 30 ug im once weekly; Interferon beta 1a, oral doxycycline; Interferon beta-1a; Interferon beta-1a (avonex); Interferon beta-1a (avonex®); Interferon beta-1a (current approved manufacturing process invloving fbs); Interferon beta-1a (new process, manufactured without fbs); Interferon beta-1a (rebif); Interferon beta-1a 30 µg; Interferon beta-1a fbs-free/hsa-free, rnf; Interferon beta-1a hsa+ biosimilar; Interferon beta-1a hsa-free biosimilar; Interferon beta-1a original; Interferon beta1a; New formulation of rebif - human interferon beta-1a; Pegylated interferon beta-1a; Rebif (interferon beta 1a); Rebif (interferon beta-1a); Rebif (interferon beta-1a), merck serono europe ltd; Recombinant human interferon beta-1a; Sc interferon beta-1a; | D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
5件: 13, 14, 26, 96, 97 |
149 | Interferon beta-1b | 21件: Betaferon® (interferon beta-1b); Betaseron (interferon beta-1b, bay86-5046); Betaseron (interferon beta-1b, bay86-5046), bayer healthcare ag; Extavia (interferon beta-1b), novartis pharma ag; Interferon beta 1b; Interferon beta 1b (betaseron, bay86-5046); Interferon beta-1b; Interferon beta-1b (betaferon, bay 86-5046); Interferon beta-1b (betaferon, bay86-5046); Interferon beta-1b (betaferon/betaseron, bay86-5046); Interferon beta-1b (betaferon®, bay 86-5046); Interferon beta-1b (betaseron, bay86-5046); Interferon beta-1b (betaseron, betaferon, bay86-5046); Interferon beta-1b (pf530, betaferon); Interferon beta-1b and tacrolimus; Interferon beta-1b group; Interferon beta-1b, (betaseron bay86-5046); Interferon beta-1b/atorvastatin group; Msdmds other than betaseron (interferon beta-1b, bay86-5046); Recombinant interferon beta-1b; Sc interferon beta-1b; | D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
150 | Iron | 14件: Injection of iron; Iron; Iron chelating agents; Iron dextran; Iron oxide; Iron sucrose; Iron sulphate; Iron sulphate 200mg coated tablets; Iron supplement; Iron supplement 300-600 mg/day; Iron(iii)- hydroxide dextran complex; Oral iron; Ultra small particles of iron oxide (uspio); Ultrasmall particles of iron oxide; | - |
- |
- |
7件: 13, 62, 86, 96, 97, 254, 284 |
151 | Isopropyl alcohol | - | D00137 |
- |
- |
10件: 13, 46, 58, 84, 96, 97, 269, 271, 279, 298 |
152 | Isoxaflutole | - | - |
- |
- |
8件: 5, 6, 13, 18, 81, 113, 149, 299 |
153 | Isoxsuprine | 2件: Isoxsuprine; Isoxsuprine hydrochloride; | D08092 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 13 |
154 | Ixazomib | 3件: Ixazomib; Ixazomib (ninlaro®) capsules; Ixazomib citrate; | D10130 |
1件: PSMB5 |
1件: Proteasome |
4件: 13, 16, 28, 61 |
155 | Ketamine | 3件: Ketamine; S-ketamine; S-ketamine & midazolam; | D00711 D08098 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
6件: 6, 13, 70, 113, 156, 215 |
156 | Ketoconazole | 2件: Dimebon + ketoconazole; Ketoconazole; | D00351 |
1件: CYP17A1 |
6件: Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis |
3件: 8, 13, 75 |
157 | L-Alanine | 1件: L-alanine; | D00012 |
- |
- |
3件: 13, 298, 299 |
158 | L-Cysteine | - | D00026 D02326 |
- |
- |
9件: 6, 13, 19, 84, 85, 88, 90, 254, 296 |
159 | L-Lysine | 2件: L-lysine; L-lysine-n-acetylcysteinate; | D02304 |
- |
- |
4件: 13, 97, 228, 299 |
160 | Lactose | 3件: Lactose; Lactose in water; Lactose monohydrate; | D00046 D03226 |
- |
- |
6件: 2, 6, 13, 97, 228, 310 |
161 | Lamotrigine | 3件: Lamotrigine; Lamotrigine dispers; Lamotrigine extended release tablets; | D00354 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
3件: 13, 34, 114 |
162 | Laquinimod | 8件: Laquinimod; Laquinimod 0.6; Laquinimod 1.2; Laquinimod capsules 0.3 mg; Laquinimod capsules 0.6 mg; Laquinimod cápsulas 0.5 mg; Laquinimod sodium (usan); Laquinimod tablets 0.3 mg; | - |
- |
- |
4件: 8, 13, 49, 96 |
163 | Levetiracetam | 1件: Levetiracetam; | D00709 |
1件: SV2A |
1件: ECM-receptor interaction |
4件: 2, 4, 6, 13 |
164 | Levocarnitine | 4件: Levocarnitine; Levocarnitine propyl hydrochloride; Valproate, levocarnitine; Valproic acid and levocarnitine; | D02030 D02176 D04713 |
- |
- |
10件: 3, 5, 13, 53, 58, 96, 97, 265, 298, 316 |
165 | Levoleucovorin | - | D04715 |
- |
- |
1件: 13 |
166 | Levonorgestrel | 1件: Levonorgestrel; | D00950 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
1件: 13 |
167 | Lidocaine | 8件: 5% lidocaine/5 mg/ml estradiol compound cream; Alkalinized lidocaine-heparin; Bladder instillation with heparin/ lidocaine; Lidocaine; Lidocaine injection 2%; Lidocaine patch 5%; Lidocaine releasing intravesical system - liris®; Local anesthesia (lidocaine hydrochloride); | D00358 D02086 D08127 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
10件: 6, 13, 46, 84, 86, 97, 168, 226, 231, 256 |
168 | Linoleic acid | 2件: Linoleic acid; Linoleic acid/oleic acid; | - |
- |
- |
1件: 13 |
169 | Liothyronine | 3件: Liothyronine; Liothyronine i 131; Liothyronine sodium; | D01011 D08128 |
2件: THRA, THRB |
2件: Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway |
3件: 13, 78, 212 |
170 | Lipoic Acid | 8件: Alpha lipoic acid; Alpha-lipoic acid; Alpha-lipoic acid and l-acetyl carnitine; Lipoic acid; Lipoic acid (la) with fish oil and la without fish oil; Lipoic acid and omega-3 fatty acids; Oral lipoic acid (la); R lipoic acid; | D00048 D00086 |
- |
- |
5件: 2, 5, 13, 14, 20 |
171 | Lisdexamfetamine | 2件: Lisdexamfetamine; Lisdexamfetamine sulfate; | D08130 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
1件: 13 |
172 | Lithium carbonate | 1件: Lithium carbonate; | D00801 |
- |
- |
8件: 2, 5, 7, 8, 13, 17, 19, 127 |
173 | Loperamide | 1件: Loperamide; | D00729 D07113 D08144 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
2件: 13, 97 |
174 | Loratadine | 1件: Loratadine; | D00364 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
3件: 6, 13, 46 |
175 | Losartan | 8件: Lisinopril, losartan, and atorvastatin; Losartan; Losartan and atenolol or propranolol; Losartan bluefish 50 mg; Losartan potasico; Losartan potassium; Losartan tablets & qingremoshen granule; Sildenafil and losartan; | D00357 D08146 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
18件: 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
176 | Lubiprostone | 1件: Lubiprostone; | D04790 |
1件: CLCN2 |
1件: Mineral absorption |
4件: 6, 13, 290, 299 |
177 | MK-0812 | 2件: Mk0812; Mk0812 / duration of treatment: 12 weeks; | - |
- |
- |
2件: 13, 46 |
178 | Magnesium | 16件: (s)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide; (s)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide; Magnesium; Magnesium citrate; Magnesium gluconate; Magnesium hydroxide; Magnesium oxide; Magnesium sulfate; Mineral boost (magnesium); Nexium (esomeprazole magnesium); Omeprazole magnesium; Saroglitazar magnesium 2 mg; Saroglitazar magnesium 4 mg; Sodium picosulfate, magnesium oxide and citric acid; Sodium picosulfate/magnesium citrate laxative; Sulfate, magnesium; | - |
- |
- |
15件: 6, 11, 13, 46, 64, 93, 97, 166, 225, 235, 284, 291, 296, 297, 298 |
179 | Maltodextrin | 3件: Maltodextrin; Maltodextrin fiber supplement; Resistant maltodextrin; | D02329 |
- |
- |
4件: 6, 13, 96, 97 |
180 | Mangafodipir | 2件: Mangafodipir; Mangafodipir (teslascan); | D08262 |
- |
- |
2件: 13, 58 |
181 | Mannose | 3件: D mannose; Mannose; Recombinant human a-glucosidase conjugated with multiple copies of synthetic bis-mannose-6-phosphate-tetra-mannose glycan (neogaa); | - |
- |
- |
2件: 13, 256 |
182 | Masitinib | 10件: Masitinib; Masitinib (3.0); Masitinib (4.5); Masitinib (6.0); Masitinib (ab1010); Masitinib 100mg; Masitinib 200mg; Masitinib 3 mg; Masitinib 6.0 mg; Masitinib mesylate; | D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
183 | Medical Cannabis | - | - |
- |
- |
6件: 2, 6, 13, 90, 96, 97 |
184 | Melatonin | 10件: 3 mg melatonin; 5 mg melatonin; Circadin ( inn= melatonin); Diazepam, melatonin; Dtr melatonin (nih cc pds); Hourly dosing of the nychtemeral secretion of melatonin; Melatonin; Melatonin cr; Melatonin pr; Melatonin(circadin®); | D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
8件: 6, 13, 46, 49, 90, 97, 144, 202 |
185 | Melphalan | 8件: Carmustine, etoposide, cytarabine, and melphalan (beam); Fludarabine, melphalan, thiotepa; Fludarabine/ melphalan; Melphalan; Melphalan hydrochloride; Melphalan, thalidomide and dexamethasone; Propylene glycol-free melphalan hydrochloride; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan; | D00369 |
- |
- |
14件: 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285 |
186 | Memantine | 3件: Memantine; Memantine (ebixa); Memantine hydrochloride; | D04905 D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
7件: 2, 6, 8, 13, 49, 127, 205 |
187 | Metformin | 12件: 750 mg metformin and 7.5 g l-citrulline daily p.o.; Glucophage (metformin); L-citrulline and metformin & l-citrulline; Metformin; Metformin (generic); Metformin 500mg; Metformin and metformin & l-citrulline; Metformin hcl; Metformin hydrochloride; Metformin/cp-690,550; Pioglitazone or metformin; Sitagliptin and metformin; | D00944 D04966 |
2件: PRKAA1, PRKAA2 |
19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
17件: 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
188 | Methamidophos | - | - |
- |
- |
12件: 2, 11, 13, 19, 46, 49, 58, 70, 85, 98, 298, 300 |
189 | Methotrexate | 81件: Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept + methotrexate; Adalimumab with methotrexate; Azathioprine or methotrexate; Bms-582949 and methotrexate; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Certolizumab pegol + methotrexate (mtx); Clobetasol propionate + methotrexate; Cp-690,550 + methotrexate; Cyclosporin, methotrexate (gvhd prophylaxis); Early immunosuppressants (azathioprine, methotrexate); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept, methotrexate, prednisolone; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Infliximab + methotrexate (mtx); Infliximab, methylprednisolone, methotrexate; Intrathecal methotrexate; Methotrexate; Methotrexate 'lederle' 2,5mg tablets; Methotrexate 'lederle' 2.5mg tablets; Methotrexate (metoject® prefilled pen); Methotrexate (mtx); Methotrexate + biologic administration; Methotrexate + infliximab; Methotrexate + methylprednisolone; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate - amneal; Methotrexate - dava; Methotrexate - delay; Methotrexate - etanercept - prednisolone arm; Methotrexate - immediate; Methotrexate 2.5 mg; Methotrexate 2.5 mg tablets; Methotrexate 2.5mg tablets; Methotrexate 2.5mg tablets bp; Methotrexate 25 mg; Methotrexate 50mg/ml solution for injection, pre-filled syringe; Methotrexate and folic acid; Methotrexate as methotrexate disodium; Methotrexate bellon; Methotrexate bellon 25mg/ml; Methotrexate capsules; Methotrexate disodium; Methotrexate lachema 5inj. sol; Methotrexate pfizer 2,5 mg tabletter; Methotrexate placebo; Methotrexate plus enbrel or enbrel alone; Methotrexate plus erb-041 for 12 weeks; Methotrexate plus sulfasalazine; Methotrexate pre-filled pen; Methotrexate prefilled pen; Methotrexate prefilled syringe; Methotrexate sodium; Methotrexate sodium 2.5mg tablets; Methotrexate sodium tablets 2.5 mg; Methotrexate treatment; Methotrexate(mtx); Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.; Methotrexate(necessary); Methotrexate*100cpr 2,5mg; Methotrexate, leucovorin and bms-986142; Methotrexate,adalimumab; Methotrexate-lachema; Methotrexate-sulfasalazine-hydroxychloroquine; Methotrexate® 2.5 mg tablets; Mp-435(dose1) + methotrexate; Mycophenolate mofetil,methotrexate; Oral methotrexate; Phase 1: methotrexate; Response to anakinra associated with methotrexate; Response to infliximab associated with methotrexate; Stable weekly dose of methotrexate; Tacrolimus with methotrexate; Tasocitinib plus methotrexate; Tocilizumab + methotrexate(mtx); Tocilizumab+methotrexate(mtx); Tofacitinib with methotrexate; Tofacitinib without methotrexate; Treatment with systemic therapy (methotrexate); Urine samples taken to measure methotrexate and its major metabolite 7-oh-methotrexate level; | D00142 D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
33件: 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
190 | Methylphenidate | 11件: D-methylphenidate; Methylphenidate; Methylphenidate (mpd); Methylphenidate (overencapsulated); Methylphenidate 10mg tablets; Methylphenidate hydrochloride; Methylphenidate modified release; Methylphenidate modified release 20 mg; Methylphenidate modified release 30 mg; Methylphenidate modified release 40 mg; Methylphenidate, fluoxetin, risperidone; | D01296 D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
7件: 6, 13, 34, 84, 113, 179, 206 |
191 | Methylprednisolone | 29件: Administration of rituximab and methylprednisolone; Corticosteroid treatment (methylprednisolone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Infliximab, methylprednisolone, methotrexate; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Intravenous methylprednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methotrexate + methylprednisolone; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone (mp); Methylprednisolone (mp) or prednisone (pred); Methylprednisolone (or other glucocorticoid); Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone mylan générique; Methylprednisolone or budesonide; Methylprednisolone or prednisolone; Methylprednisolone pulse; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides; | D00407 D00751 D00979 D05000 D05001 D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
192 | Methylprednisolone hemisuccinate | 1件: Methylprednisolone hemisuccinate; | D05000 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 13, 97 |
193 | Midazolam | 6件: Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Midazolam; Midazolam 2 mg; Midazolam 3 mg; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; S-ketamine & midazolam; | D00550 D00696 D05028 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
10件: 2, 3, 6, 13, 46, 70, 96, 97, 231, 298 |
194 | Minocycline | 7件: Combination of minocycline and mtx or mtx alone; Glatiramer acetate with minocycline; Lovastatin, then minocycline/lovastatin; Minocycline; Minocycline 100 mg film-coated tablets; Minocycline hydrochloride; Minocycline, then minocycline/lovastatin; | D00850 D05045 |
- |
- |
14件: 2, 6, 8, 13, 46, 84, 85, 90, 94, 162, 201, 206, 280, 299 |
195 | Mirabegron | 1件: Mirabegron; | D09535 |
1件: ADRB3 |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cGMP-PKG signaling pathway |
3件: 6, 13, 226 |
196 | Mitoquinone | 1件: Mitoquinone; | - |
- |
- |
1件: 13 |
197 | Mitoxantrone | 3件: Dexrazoxane (drz) plus mitoxantrone (mx); Glatiramer acetate 20 mg, with mitoxantrone; Mitoxantrone; | D02166 D08224 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
1件: 13 |
198 | Modafinil | 4件: Modafinil; Modafinil 50mg; Over-encapsulated modafinil; Provigil (modafinil); | D01832 |
- |
- |
4件: 6, 13, 49, 93 |
199 | Montelukast | 8件: 5 mg montelukast; Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Montelukast; Montelukast sodium; Montelukast teva; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; Montelukast/ singulair; Singulair (montelukast sodium); | D00529 D08229 |
1件: CYSLTR1 |
2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction |
5件: 13, 46, 85, 98, 228 |
200 | Mycophenolate mofetil | 17件: Azathioprine or mycophenolate mofetil; Cellcept (mycophenolate mofetil); Cyclosporine combine with mycophenolate mofetil; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Mycophenolate mofetil; Mycophenolate mofetil (cellcept); Mycophenolate mofetil (mmf); Mycophenolate mofetil (mmf) 3 g/day; Mycophenolate mofetil 2 g/day; Mycophenolate mofetil [cellcept]; Mycophenolate mofetil orally 1000 mg twice a day (bid); Mycophenolate mofetil plus lower dose of prednisone; Mycophenolate mofetil(mmf); Mycophenolate mofetil, low dose steroid; Mycophenolate mofetil,methotrexate; Prednisolone and mycophenolate mofetil; Prednisone and mycophenolate mofetil; | D00752 D05094 D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
32件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
201 | Mycophenolic acid | 2件: Mycophenolic acid; Mycophenolic acid mofetil; | D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
34件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 |
202 | Nabilone | 3件: Cesamet™ (nabilone); Nabilone; Nabilone 0.25 mg; | D05099 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
2件: 6, 13 |
203 | Naltrexone | 5件: 4.5 mg naltrexone; Low dose naltrexone; Naltrexone; Naltrexone hydrochloride; Naltrexone-hcl; | D02095 D05113 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
204 | Naproxen | 12件: Comparator: naproxen tablet 500 mg; Naproxen; Naproxen (ec-narosyn) delayed release tables, 375 (syntex (usa), inc.); Naproxen 10 mg/kg; Naproxen 500 mg tablets (pn 200 minus omeprazole); Naproxen delayed release tables, 375 (gevena pharmaceuticals, inc.); Naproxen oral suspension; Naproxen pch tablet 500mg; Naproxen sodium 550mg tablet; Part i- naproxen 1000 mg; Part ii- naproxen 1000 mg; Pn 200 tablets (500 mg naproxen and 20 mg omeprazole); | D00118 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
3件: 13, 46, 271 |
205 | Natalizumab | 12件: Bg00002 (natalizumab); Bg00002-e (natalizumab high titer); Bg0002 (natalizumab); Natalizumab; Natalizumab (bg00002); Natalizumab (ntz); Natalizumab (tysabri); Natalizumab for iv infusion; Natalizumab for subcutaneous injection; Natalizumab treatment; Tysabri ® (natalizumab); Tysabri® (natalizumab); | D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
6件: 13, 15, 25, 46, 63, 96 |
206 | Nerispirdine | 3件: Nerispirdine; Nerispirdine (hp184); Nerispirdine hydrochloride; | - |
- |
- |
1件: 13 |
207 | Nicotinamide | 2件: Nicotinamide; Nicotinamide riboside; | D00036 |
- |
- |
8件: 5, 6, 13, 46, 49, 53, 67, 162 |
208 | Nitrofurantoin | 1件: Nitrofurantoin; | D00439 |
- |
- |
1件: 13 |
209 | Nivolumab | 1件: Nivolumab; | D10316 |
1件: PDCD1 |
3件: Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway |
10件: 13, 26, 41, 46, 49, 50, 51, 53, 96, 97 |
210 | Nomegestrol | 2件: Nomegestrol; Nomegestrol acetate; | D07222 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
1件: 13 |
211 | Nomegestrol acetate | 1件: Nomegestrol acetate; | D08281 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
1件: 13 |
212 | Norethisterone | - | D00182 D00953 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
4件: 13, 46, 49, 299 |
213 | Ocrelizumab | 10件: Ocrelizumab; Ocrelizumab / rhumab 2h7; Ocrelizumab 300 mg; Ocrelizumab 300mg; Ocrelizumab 300mg /10ml; Ocrelizumab 300mg/10ml; Ocrelizumab 500mg; Ocrelizumab 600 mg; Ocrelizumab dose 1; Ocrelizumab dose 2 and dose 3; | D05218 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
3件: 13, 46, 49 |
214 | Ofatumumab | 8件: Ofatumumab; Ofatumumab 100; Ofatumumab 300; Ofatumumab 30mg; Ofatumumab 3mg; Ofatumumab 60mg; Ofatumumab 700; Ofatumumab subcutaneous injection; | D09314 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
3件: 13, 35, 46 |
215 | Olea europaea leaf | - | - |
- |
- |
3件: 13, 49, 53 |
216 | Oleic Acid | 2件: Linoleic acid/oleic acid; Oleic acid; | D02315 |
- |
- |
1件: 13 |
217 | Olive oil | 2件: Freshly-pressed extra virgin olive oil; Olive oil; | D03311 |
- |
- |
4件: 13, 49, 53, 96 |
218 | Omega-3 fatty acids | 6件: Dietary supplement omega3 fatty acids aand vitamins; Lipoic acid and omega-3 fatty acids; Omega 3 fatty acids; Omega-3 fatty acids; Omega3 fatty acids; Triomar™ (omega-3 fatty acids); | - |
- |
- |
7件: 13, 46, 49, 66, 79, 96, 299 |
219 | Omeprazole | 16件: Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Clartihromycin, amoxicillin, and omeprazole; Diclofenac + omeprazole; Dimebon + omeprazole; Naproxen 500 mg tablets (pn 200 minus omeprazole); Omeprazole; Omeprazole (uk licensed generic product); Omeprazole 20 mg; Omeprazole 20mg; Omeprazole 20mg bid; Omeprazole 40 mg; Omeprazole 40mg capsule; Omeprazole magnesium; Omeprazole rectally 1mg/kg; Pn 200 tablets (500 mg naproxen and 20 mg omeprazole); Rifaximin+omeprazole+miralax; | D00455 D01207 D05259 D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
15件: 6, 8, 13, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
220 | Opicinumab | 2件: Biib033 (opicinumab); Opicinumab; | - |
- |
- |
1件: 13 |
221 | Oxcarbazepine | 1件: Oxcarbazepine; | D00533 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 13 |
222 | Oxycodone | 14件: Extended-release oxycodone; Oxycodone; Oxycodone by patient-controlled analgesia (pca); Oxycodone depot ”sandoz”, depot tablets; Oxycodone hydrochloride; Oxycodone naloxone prolonged release tablets; Oxycodone orion; Oxycodone/acetaminophen; Oxycodone/naloxone prolonged release t; Oxycodone/naloxone prolonged release tablets; Oxycodone/naloxone prolonged release tablets 10/5 mg; Oxycodone/naloxone prolonged release tablets 20/10 mg; Oxycodone/naloxone prolonged release tablets 5/2.5 mg; Pr oxycodone; | D03783 D05312 D05462 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
7件: 6, 13, 46, 70, 226, 231, 298 |
223 | Oxyquinoline | - | D05321 |
- |
- |
1件: 13 |
224 | Ozanimod | 5件: Ozanimod; Ozanimod 0.5 mg; Ozanimod 1 mg; Ozanimod hydrochloride; Rpc1063 (equivalent to ozanimod hcl); | D10968 |
5件: S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
3件: 13, 96, 97 |
225 | Palifermin | 1件: Palifermin; | D05338 |
1件: FGFR2 |
12件: Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells |
4件: 13, 38, 39, 65 |
226 | Panax quinquefolius whole | - | - |
- |
- |
2件: 13, 46 |
227 | Pantoprazole | 1件: Pantoprazole; | D02593 D05353 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
2件: 13, 65 |
228 | Paroxetine | 3件: Paroxetine; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; | D02260 D02362 D05374 D05375 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 6, 13, 46 |
229 | Peginterferon beta-1a | 4件: Biib017 (peginterferon beta-1a); Peginterferon beta-1a; Plegridy (peginterferon beta-1a), biogen idec ltd; Sc peginterferon beta-1a; | D10483 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
230 | Pentaerythritol tetranitrate | - | D01721 |
- |
- |
1件: 13 |
231 | Pentetic acid | - | D05422 |
- |
- |
3件: 13, 28, 299 |
232 | Pepinemab | - | D11469 |
1件: SEMA4D |
1件: Axon guidance |
2件: 8, 13 |
233 | Phenytoin | 1件: Phenytoin; | D00512 D02103 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 13 |
234 | Phosphate ion | - | - |
- |
- |
29件: 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
235 | Phylloquinone | 2件: Phylloquinone; Phylloquinone (vitamin k1); | D00148 |
- |
- |
4件: 13, 46, 96, 288 |
236 | Pioglitazone | 6件: Actos (pioglitazone); Pioglitazone; Pioglitazone 15 mg; Pioglitazone and tretinoin; Pioglitazone or metformin; Tretinoin and pioglitazone hcl; | D00945 D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
237 | Pixantrone | 1件: Pixantrone; | D05522 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
2件: 11, 13 |
238 | Ponesimod | 4件: Ponesimod; Ponesimod 10 mg; Ponesimod 20 mg; Ponesimod 40 mg; | D11215 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
239 | Pravastatin | 4件: Lonafarnib, zoledronic acid, and pravastatin; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; Pravastatin; Pravastatin sodium; | D00893 D08410 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
9件: 13, 46, 49, 67, 79, 96, 164, 265, 333 |
240 | Prednisolone | 46件: Azd4017 and prednisolone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroid (prednisolone); Corticosteroid treatment (methylprednisolone or prednisolone); Corticosteroids (prednisone or prednisolone); Etanercept, methotrexate, prednisolone; Glucocorticoid (prednisone or prednisolone); Intravenous methyl prednisolone; Long-circulating liposomal prednisolone; Low dose prednisolone; Medium dose prednisolone; Methotrexate - etanercept - prednisolone arm; Methyl prednisolone; Methylprednisolone or prednisolone; Oral prednisolone; Overencapsulated prednisolone tablets; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; Peg-liposomal prednisolone sodium phosphate; Prednisolone; Prednisolone & dipyridamole; Prednisolone + mabthera; Prednisolone 1mg tablets; Prednisolone 20 mg; Prednisolone 40 mg; Prednisolone 5 mg; Prednisolone 5mg tablet; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil; Prednisolone and taper; Prednisolone sodium metasulphobenzoate; Prednisolone sodium phosphate; Prednisolone sodium succinate; Prednisolone tablets b.p. 5mg; Prednisolone tablets bp; Prednisolone tablets usp 5 mg; Prednisolone-dipyridamole; Prednisone or prednisolone; Prednisone/prednisolone; Pyridoxine plus prednisolone; Soluble prednisolone tablets; Sulphasalazine + hydroxychloroquine or prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Z102 (prednisolone and dipyridamole).; | D00472 D00980 D00981 D00982 D01239 D01998 D02156 D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
241 | Prednisone | 57件: 0 mg prednisone; 5 mg prednisone; 5-aminosalicylic acid(5-asa) and/or prednisone; 5-asa, prednisone, azathioprine or remicade; Azathioprine/prednisone; Chinese herb prescription granule plus prednisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Glucocorticoid (prednisone or prednisolone); Granulocyte-colony stimulating factor (g-csf) and prednisone; Hormone (prednisone); Hydroxychloroquine + prednisone; Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Mycophenolate mofetil plus lower dose of prednisone; Oral prednisone; Oral prednisone 5mg; Over encapsulated prednisone; Prednisone; Prednisone (and methylprednisolone); Prednisone + inhibace/cozaar; Prednisone - azathioprine; Prednisone 0,5 mg/kg orally on alternate days; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Prednisone acetate; Prednisone acetate tablets; Prednisone alone; Prednisone and cyclophosphamide; Prednisone and mycophenolate mofetil; Prednisone and ustekinumab treatment; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone capsules; Prednisone discontinuation; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Prednisone, cyclophosphamide; Prednisone, fk506, mmf; Prednisone, methylprednisolone,cyclophosphamides; Prednisone/prednisolone; Rayos (delayed-release prednisone); Sotatercept with prednisone boost; Tacrolimus combined with prednisone; Thalidomide, cyclophosphamide and prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone); | D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
44件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 145, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
242 | Pregabalin | 3件: Antioxidant plus pregabalin; Pregabalin; Pregabalin 75mg; | D02716 |
4件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4 |
7件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway |
5件: 13, 36, 46, 70, 298 |
243 | Prucalopride | 2件: Prucalopride; Prucalopride succinate; | D09205 |
1件: HTR4 |
4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, cAMP signaling pathway |
3件: 13, 51, 96 |
244 | Quetiapine | 2件: Extended-release quetiapine fumarate; Quetiapine; | D00458 D08456 |
2件: DRD2, HTR2A |
11件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway |
2件: 6, 13 |
245 | Quinidine | 5件: Dextromethorphan hbr and quinidine sulfate; Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg; Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg; Dextromethorphan/quinidine 20mg/10mg (dm/q 20mg/10mg); Quinidine; | D00642 D00643 D02272 D08458 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
3件: 2, 8, 13 |
246 | Rabbit | 15件: Anti-thymocyte globulin (rabbit); Anti-thymocyte globulin, rabbit; Antithymocyte globulin (rabbit); Antithymocyte immunoglobulin (rabbit); Cyclophosphamide, fludarabine, rabbit atg; Rabbit; Rabbit anti-thymocyte globulin; Rabbit anti-thymocyte globulin (atg); Rabbit antithymocyte globulin; Rabbit antithymoglobulin (atg); Rabbit atg; Rabbit atg, (genzyme); Rabbit atg, cyclosporine, levamisole; Rabbit atg, thymoglobuline (genzyme); Rabbit human t lymphocyte immunoglobulin; | - |
- |
- |
7件: 13, 49, 51, 60, 65, 96, 285 |
247 | Raltegravir | 2件: Raltegravir; Raltegravir and zidovudine; | D06676 |
- |
- |
4件: 13, 26, 93, 265 |
248 | Ramatroban | 1件: Ramatroban; | D01128 |
2件: PTGDR, TBXA2R |
3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation |
1件: 13 |
249 | Ranitidine | 1件: Ranitidine; | D00422 D00673 |
1件: HRH2 |
3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
2件: 13, 65 |
250 | Riboflavin | 4件: Cofactor supplementation (thiamine, riboflavin, l-carnitine); Riboflavin; Riboflavin sodium phosphate injection; Riboflavin supplementation; | D00050 D01622 D01913 |
- |
- |
9件: 13, 38, 46, 49, 96, 97, 162, 168, 265 |
251 | Rifampicin | 1件: Rifampicin; | D00211 |
- |
- |
7件: 6, 13, 17, 46, 84, 86, 299 |
252 | Riluzole | 5件: Riluzole; Riluzole 50 mg; Riluzole 50 mg (part b); Riluzole oral soluble film; Riluzole oral soluble film (rosf) 50 mg; | D00775 |
14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway |
7件: 2, 3, 5, 8, 13, 17, 206 |
253 | Rituximab | 52件: Abatacept, rituximab or tocilizumab; Abp 798 - biosimilar to rituximab; Administration of rituximab and methylprednisolone; Alemtuzumab and rituximab; Alemtuzumab, rituximab; Bendamustine, rituximab; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Combined plasma exchange (pex), rituximab, and corticosteroids; Dexamethasone and rituximab; Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab); Gp2013 - a proposed biosimilar rituximab; Idec-c2b8 (rituximab); Immunosuppressive treatment (eg, rituximab); Individualized dose of rituximab; Intravenous rituximab; Mabthera (rituximab); Mabthera or biosimilar rituximab; Mabthera or biosimilar rituximab product; Mabthera® (rituximab); Originator rituximab - rituxan ® or mabthera ®; Rhtpo in combination with rituximab; Rituxan (inn: rituximab), brand name in the united states; Rituxan (rituximab); Rituxan® (rituximab); Rituximab; Rituximab (anti-cd20); Rituximab (arm a); Rituximab (arm b); Rituximab (mabthera® or rituxan®).; Rituximab (mabthera®); Rituximab (rituxan); Rituximab (rtx) and azathioprine (aza); Rituximab - mabthera; Rituximab 1g iv; Rituximab [mabthera/rituxan]; Rituximab [mabthera]; Rituximab and cyclophosphamide iv; Rituximab combined with omalizumab; Rituximab infusion; Rituximab it; Rituximab iv; Rituximab mabthera; Rituximab or rituximab hyaluronidase human; Rituximab, mtx, folic acid; Rituximab, observational study amon patients with active ra; Rituximab-eu+ rituximab-pfizer x 2 courses; Rituximab-pfizer (pf-05280586) x 3 courses; Rituximab-us + rituximab-pfizer x 2 courses; Rituximab/ mabthera; Sait101 (proposed rituximab biosimilar); Standard dose of rituximab; The standard steroid treatment, plasma exchange and rituximab; | D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
42件: 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
254 | Rivastigmine | 5件: Exelon patch (rivastigmine transdermal system); Rivastigmine; Rivastigmine capsule; Rivastigmine patch 9.5 cm2; Rivastigmine transdermal patch; | D02558 D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
3件: 5, 6, 13 |
255 | Rolipram | 1件: Rolipram; | D01783 |
4件: PDE4A, PDE4B, PDE4C, PDE4D |
5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
2件: 8, 13 |
256 | Salbutamol | 5件: Nebulized combination ipratropium bromide with salbutamol; R-salbutamol; R-salbutamol sulphate; Salbutamol; Salbutamol 4mg tablet; | D02147 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
13件: 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
257 | Secukinumab | 12件: 150 mg double-blinded secukinumab; 150 mg open-label secukinumab; 300 mg double-blinded secukinumab; Ain457/secukinumab; Secukinumab; Secukinumab (150 mg); Secukinumab (75 mg); Secukinumab (ain457); Secukinumab 150 milligram [cosentyx]; Secukinumab 150mg; Secukinumab 300 mg, s.c.; Secukinumab 300mg; | D09967 |
1件: IL17A |
5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Rheumatoid arthritis, Th17 cell differentiation |
7件: 13, 37, 41, 46, 160, 269, 271 |
258 | Selenious acid | - | D05814 |
- |
- |
2件: 13, 278 |
259 | Selenium | 2件: Selenium; Vitamin e/selenium; | - |
- |
- |
2件: 13, 278 |
260 | Silicon dioxide | - | D06521 |
- |
- |
2件: 13, 96 |
261 | Silodosin | 1件: Silodosin; | D01965 |
1件: ADRA1A |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 6, 13 |
262 | Simethicone | 1件: Simethicone; | D05841 |
- |
- |
2件: 13, 96 |
263 | Simvastatin | 11件: Encapsulated simvastatin tablets; Ezetimibe+simvastatin drug combination; Simvastatin; Simvastatin 20mg/5ml oral suspension; Simvastatin 40 mg film-coated tablets; Simvastatin 40mg; Simvastatin alternova; Simvastatin susp.; Simvastatin treatment for 28 days; Simvastatin-ratiopharm; Simvastatin-ratiopharm®; | D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
264 | Siponimod | 5件: Siponimod; Siponimod 0.25 mg tablet; Siponimod 0.5 mg tablet; Siponimod 1 mg tablet; Siponimod 2 mg tablet; | D11460 |
2件: S1PR1, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
2件: 13, 50 |
265 | Sirolimus | 14件: Rapamycin, sirolimus; Sirolimus; Sirolimus (formerly known as rapamycin); Sirolimus 0,1% crème; Sirolimus 0.2%; Sirolimus 0.4%; Sirolimus 2 mg; Sirolimus 2%; Sirolimus and hydroxychloroquine; Sirolimus oral liquid product 1mg/ml; Sirolimus, 2%; Skincerity plus sirolimus/rapamycin; Skinercity plus sirolimus/rapamycin; Topical 0.1% sirolimus; | D00753 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
266 | Sivelestat | 1件: Sivelestat; | D03788 |
1件: ELANE |
2件: Systemic lupus erythematosus, Transcriptional misregulation in cancer |
3件: 13, 85, 96 |
267 | Sodium chloride | 14件: 0.9% sodium chloride; 0.9% sodium chloride (normal saline); 0.9% sodium chloride injection; 0.9% w/v sodium chloride solution; Isotonic sodium chloride solution; Physiological serum (sodium chloride); Sodium chloride; Sodium chloride (7%); Sodium chloride 0,9%; Sodium chloride 6%; Sodium chloride solution; Sodium chloride solution 0.9%; Sodium chloride solvent; Sodium pyruvate in 0.9% sodium chloride solution; | D02056 |
- |
- |
19件: 6, 11, 13, 14, 17, 34, 46, 51, 53, 67, 78, 86, 97, 168, 193, 227, 228, 288, 299 |
268 | Sodium fluoride | 2件: Sodium fluoride; Sodium fluoride 18f; | D00943 |
- |
- |
2件: 13, 51 |
269 | Somatorelin | 1件: Somatorelin; | D08523 |
1件: GHRHR |
2件: Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction |
2件: 13, 78 |
270 | Somatotropin | 2件: Recombinant human somatotropin; Somatotropin; | D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
18件: 2, 3, 13, 19, 46, 74, 75, 78, 96, 113, 191, 193, 195, 236, 265, 274, 276, 299 |
271 | Sulfate ion | - | - |
- |
- |
22件: 2, 6, 11, 13, 26, 34, 36, 46, 49, 60, 61, 64, 66, 79, 86, 96, 222, 226, 265, 296, 297, 299 |
272 | Suvorexant | 1件: Suvorexant; | D10082 |
2件: HCRTR1, HCRTR2 |
1件: Neuroactive ligand-receptor interaction |
3件: 5, 6, 13 |
273 | TRO19622 | 2件: Olesoxime (tro19622); Tro19622; | - |
- |
- |
3件: 2, 3, 13 |
274 | Tacrolimus | 13件: Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Interferon beta-1b and tacrolimus; Lcp-tacro (tacrolimus); Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Rectal tacrolimus; Tacrolimus; Tacrolimus (prograf®); Tacrolimus and mmf; Tacrolimus capsule; Tacrolimus capsules; Tacrolimus combined with prednisone; Tacrolimus prolonged-release hard capsules; Tacrolimus with methotrexate; | D00107 D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
30件: 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 86, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
275 | Tarenflurbil | 1件: Tarenflurbil; | D09010 |
4件: APH1A, NCSTN, PSEN1, PSENEN |
5件: Alzheimer disease, Human papillomavirus infection, Neurotrophin signaling pathway, Notch signaling pathway, Wnt signaling pathway |
1件: 13 |
276 | Taurine | 1件: Taurine; | D00047 |
- |
- |
1件: 13 |
277 | Tauroursodeoxycholic acid | 2件: Tauroursodeoxycholic acid; Tauroursodeoxycholic acid capsules; | - |
- |
- |
4件: 2, 13, 93, 299 |
278 | Temsirolimus | 2件: Temsirolimus; Temsirolimus tablets; | D06068 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
4件: 13, 34, 89, 331 |
279 | Teriflunomide | 6件: Teriflunomide; Teriflunomide (hmr1726); Teriflunomide 14 mg; Teriflunomide 14 mg oral tablet [aubagio]; Teriflunomide hmr1726; Teriflunomide orally; | D10172 |
1件: DHODH |
2件: Metabolic pathways, Pyrimidine metabolism |
2件: 13, 25 |
280 | Testosterone | 7件: Nebido® testosterone undecanoate 1000 mg/4 ml solution for injection; Sustanon (testosterone); Testosterone; Testosterone enanthate; Testosterone plus somatropin; Testosterone undecanoate; Transdermal testosterone gel; | D00075 D00957 D00958 D00959 D06085 D06087 |
1件: AR |
3件: Oocyte meiosis, Pathways in cancer, Prostate cancer |
7件: 1, 2, 3, 13, 78, 113, 265 |
281 | Testosterone undecanoate | 2件: Nebido® testosterone undecanoate 1000 mg/4 ml solution for injection; Testosterone undecanoate; | D06087 |
1件: AR |
3件: Oocyte meiosis, Pathways in cancer, Prostate cancer |
1件: 13 |
282 | Tetracycline | 4件: Amoxicillin and tetracycline; Amoxicillin, metronidazole and tetracycline; Tetracycline; Tetracycline - statin - antimycotic; | D00201 |
- |
- |
5件: 13, 36, 46, 53, 97 |
283 | Thiamine | 2件: Cofactor supplementation (thiamine, riboflavin, l-carnitine); Thiamine; | D08580 |
- |
- |
3件: 13, 49, 265 |
284 | Thiotepa | 5件: Fludarabine, melphalan, thiotepa; Thiotepa; Thiotepa--escalated dose; Thiotepa--single daily dose; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan; | D00583 |
- |
- |
11件: 13, 19, 20, 28, 51, 60, 65, 85, 96, 164, 284 |
285 | Tizanidine | 4件: Sublingual tizanidine 12 mg; Tizanidine; Tizanidine (sublingual or oral); Tizanidine hydrochloride capsule; | D00776 D08611 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 13 |
286 | Tocilizumab | 25件: Abatacept, rituximab or tocilizumab; Corticoids+ tocilizumab 8mg/kg/4 weeks; Decrease tocilizumab, abatacept; Inn-tocilizumab; Intra-articular tocilizumab; Mra (tocilizumab); Mra(tocilizumab); Subcutaneous tocilizumab; Tocilizumab; Tocilizumab (actemra®); Tocilizumab (mra-sc); Tocilizumab + glucocorticoids (gcs); Tocilizumab + methotrexate(mtx); Tocilizumab 162 mg; Tocilizumab 162mg/0.9ml jeringa sc; Tocilizumab [roactemra/actemra]; Tocilizumab [roactemra]; Tocilizumab infusion roacemtra (eu); Tocilizumab injection; Tocilizumab prefilled syringe; Tocilizumab sc; Tocilizumab sc 162 mg/0.9 ml prefilled syringe with safety device (pfs); Tocilizumab treatment; Tocilizumab+methotrexate(mtx); Tocilizumab, abatacept; | D02596 |
1件: IL6R |
11件: Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
287 | Tocopherol | 5件: Alpha-tocopherol; Gamma-tocopherol; Tocopherol; Tocopherol (vit e); Tocopherol acetate; | D02332 |
- |
- |
4件: 13, 49, 90, 257 |
288 | Tolperisone | 3件: Tolperisone; Tolperisone hc1; Tolperisone hcl; | D08617 |
- |
- |
1件: 13 |
289 | Topramezone | - | - |
- |
- |
7件: 6, 13, 46, 50, 96, 97, 299 |
290 | Treosulfan | 3件: Ovastat 1000 (treosulfan injection); Ovastat 5000 (treosulfan injection); Treosulfan; | D07253 |
- |
- |
3件: 13, 19, 65 |
291 | Triamcinolone | 10件: Bladder instillation with triamcinolone acetonide; Bladder instillation without triamcinolone acetonide; Bupivacaine & triamcinolone acetonide; Intra plexus triamcinolone and bupivicaine injection; Triamcinolone; Triamcinolone acetonide; Triamcinolone acetonide and normal saline solution; Triamcinolone hexacetonid (lederspan); Triamcinolone hexacetonide; Triamcinolone hexacetonide (lederspan); | D00385 D00983 D00984 D00985 D06216 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
18件: 6, 10, 13, 35, 40, 41, 42, 43, 44, 45, 46, 56, 70, 90, 96, 97, 226, 298 |
292 | Tricaprylin | - | - |
- |
- |
1件: 13 |
293 | Tricyclazole | - | - |
- |
- |
1件: 13 |
294 | Ublituximab | 1件: Ublituximab; | D11243 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
295 | Ustekinumab | 32件: Evaluation of biological predictive factors of clinical response to ustekinumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Placebo ustekinumab; Prednisone and ustekinumab treatment; Stelara (ustekinumab); Subcutaneous ustekinumab; Ustekinumab; Ustekinumab (6 mg/kg); Ustekinumab (90 mg); Ustekinumab (approximately 6 mg/kg); Ustekinumab 130 mg iv; Ustekinumab 180 mg; Ustekinumab 1mg/kg (ip); Ustekinumab 3 mg/kg (ip); Ustekinumab 4.5 mg/kg; Ustekinumab 45 mg; Ustekinumab 6 mg/kg; Ustekinumab 6 mg/kg (ip); Ustekinumab 90 mg; Ustekinumab 90 mg (sc) group 1; Ustekinumab 90 mg (sc) group 2; Ustekinumab 90 mg sc q12w; Ustekinumab 90 mg sc q8w; Ustekinumab 90 milligram (mg); Ustekinumab approximately 6 mg/kg (iv); Ustekinumab iv; Ustekinumab iv - nonresponder - ustekinumab 90mg sc (mp); Ustekinumab iv - responder - ustekinumab 90mg sc (mp); Ustekinumab iv infusion; Ustekinumab liquid in prefilled syringe; Ustekinumab sc; Ustekinumab sc injection; | D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
16件: 13, 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 |
296 | Vardenafil | 2件: Vardenafil; Vardenafil (hidrocloride); | D02731 D03260 D08668 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
3件: 13, 86, 299 |
297 | Vatelizumab | 1件: Vatelizumab; | - |
- |
- |
1件: 13 |
298 | Venlafaxine | 3件: Efexor xl 75 mg (venlafaxine); Venlafaxine; Venlafaxine hydrochloride; | D00821 D08670 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 6, 13, 46 |
299 | Vitamin A | 1件: Vitamin a; | D00069 D06543 |
2件: RARA, RARB |
8件: Acute myeloid leukemia, Estrogen signaling pathway, Gastric cancer, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer |
4件: 13, 49, 53, 90 |
300 | Vitamin D | 16件: 10000iu vitamin d; 19 nor vitamin d; 25oh-vitamin d; 5000iu vitamin d; Alendronate versus alfacalcidol (1-alpha oh vitamin d); High-dose vitamin d (2000 iu per day); Low dose arm receiving neutral oil and 400 iu/g of vitamin d every second day; Standard-dose vitamin d (400iu per day); Verum arm receiving vitamin d oil; Vitamin d; Vitamin d 100ug; Vitamin d 10ug; Vitamin d 25(oh)d; Vitamin d in arm b; Vitamin d oil; Vitamin d powder; | - |
- |
- |
18件: 13, 19, 41, 46, 49, 50, 68, 93, 95, 96, 98, 179, 222, 228, 235, 274, 298, 299 |
301 | Vitamin E | 8件: Coenzyme q10 with vitamin e; Omega-3 and vitamin e supplementation; Vitamin c 10mg/kg vitamin e 10 mg/kg; Vitamin e; Vitamin e - tgps; Vitamin e 800iu; Vitamin e supplement; Vitamin e/selenium; | D02331 |
- |
- |
12件: 2, 6, 13, 20, 46, 49, 90, 96, 97, 206, 299, 317 |
302 | Warfarin | 4件: S-warfarin; The generic name is warfarin and many producers will be involved; Warfarin; Warfarin 10 mg; | D00564 D01280 D08682 |
2件: NQO1, VKORC1 |
5件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
10件: 6, 8, 13, 19, 46, 49, 66, 85, 88, 96 |
303 | Water | 13件: 15 o water; 15-o labeled water; 5% glucose water solution; Dextrose, 5% in water; High water intake; Lactose in water; Pl 12185/0002 & pl 12185/0005(water for injection); Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; Water; Water for injection; Water for injections; Water for injections, ep; | D00001 |
- |
- |
22件: 2, 5, 6, 13, 17, 19, 28, 35, 46, 53, 57, 63, 65, 67, 78, 84, 97, 193, 226, 271, 278, 299 |
304 | Zoledronic acid | 4件: Lonafarnib, zoledronic acid, and pravastatin; Zoledronic acid; Zoledronic acid 5mg/bag 100ml inj; Zoledronic acid monohydrate; | D01968 D06378 D06379 D08689 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
11件: 6, 13, 46, 65, 93, 95, 96, 271, 274, 299, 333 |
305 | gamma-Tocopherol | 1件: Gamma-tocopherol; | - |
- |
- |
1件: 13 |
306 | keyhole limpet hemocyanin | 3件: Keyhole limpet hemocyanin; Keyhole limpet hemocyanin (klh); Keyhole limpet hemocyanin (klh) neo-antigen; | - |
- |
- |
2件: 13, 46 |